Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
December 17, 2007

Oxford Genome Sciences Allies with Amgen on Cancer Therapeutics

  • Oxford Genome Sciences (OGeS) and Amgen inked an agreement to discover, develop, and commercialize therapeutic antibodies for the treatment of cancer. Through this collaboration, OGeS hopes to strengthen its pipeline of fully human therapeutic antibodies for cancer based on the target discovery capabilities of its Oxford Genome Anatomy Project (OGAP®) database.

    The companies will generate the antibodies using Amgen's XenoMouse® technology and raise them against the druggable targets that OGeS has identified through OGAP.

    Up to six oncology programs are covered by this agreement. Amgen will have the right to select up to three programs, while OGeS will retain rights to the remainder. Once Amgen has produced the initial antibody leads, OGeS will carry out the initial preclinical assessment of each antibody program.

  • You’re all set! Thank you for subscribing to GEN Highlights.